文献速递肝病

质子泵抑制剂暴露与肝硬化患者关键肝脏相关结局的关联:退伍军人事务部队列研究

The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study.
PubMed 文献 · Gastroenterology · 2022-04-06

该回顾性队列研究纳入退伍军人健康管理局76,251例肝硬化患者,其中23,628例基线使用质子泵抑制剂(PPI)。经逆概率治疗加权校正后,PPI暴露与严重感染(HR 1.21)和失代偿(HR 1.64)风险增加相关,并可能介导肝相关死亡;但曾因消化道出血住院者全因死亡风险降低(HR 0.88)。

要点

  • PPI暴露与肝硬化患者严重感染风险增加相关(HR 1.21,95%CI 1.18-1.24,P<.001)。
  • PPI暴露与失代偿风险增加相关(HR 1.64,95%CI 1.61-1.68,P<.001)。
  • 有消化道出血住院史者PPI暴露与全因死亡风险降低相关(HR 0.88,95%CI 0.84-0.91,P<.001)。

核心结论

  • PPI暴露与肝硬化患者感染和失代偿风险增加相关,可能介导肝相关死亡。
  • 有既往消化道出血者使用PPI与全因死亡风险降低相关,提示在有适当指征时可能获益。

研究设计与样本

  • 回顾性研究,纳入退伍军人健康管理局76,251例肝硬化患者,其中23,628例基线使用PPI。
  • PPI暴露定义为从肝硬化诊断索引时间开始的时间更新变量。
  • 采用逆概率治疗加权调整的Cox回归,并进一步调整关键时间变化协变量,包括心血管合并症、消化道出血和他汀暴露。

主要发现

  • 二分类PPI暴露(是/否)在有消化道出血住院史患者中与全因死亡风险降低相关(HR 0.88,95%CI 0.84-0.91,P<.001),在其他患者中无显著关联(HR 0.99,95%CI 0.97-1.02,P=.58)。
  • 累积PPI暴露在无消化道出血住院史患者中与死亡风险增加相关(每320 mg-月奥美拉唑等效剂量HR 1.07,95%CI 1.06-1.08,P<.001)。
  • PPI暴露与严重感染显著相关(HR 1.21,95%CI 1.18-1.24,P<.001)。
  • PPI暴露与失代偿显著相关(HR 1.64,95%CI 1.61-1.68,P<.001)。
  • 病因特异性死亡分析中,PPI暴露与肝相关死亡风险增加相关(HR 1.23,95%CI 1.19-1.28),与非肝相关死亡风险降低相关(HR 0.88,95%CI 0.85-0.91)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The impact of proton pump inhibitory (PPI) medications on adverse outcomes in cirrhosis remains controversial. We aimed to evaluate the association between PPI exposure and all-cause mortality, infection, and decompensation in a large national cohort. METHODS: This was a retrospective study of patients with cirrhosis in the Veterans Health Administration. PPI exposure was classified as a time-updating variable from the index time of the cirrhosis diagnosis. Inverse probability treatment weighting-adjusted Cox regression was performed with additional adjustment for key time-varying covariates, including cardiovascular comorbidities, gastrointestinal bleeding (GIB), and statin exposure. RESULTS: The study included 76,251 patients, 23,628 of whom were on a PPI at baseline. In adjusted models, binary (yes/no) PPI exposure was associated with reduced hazard of all-cause mortality in patients with hospitalization for GIB (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.84-0.91; P < .001) but had no significant association in all others (HR, 0.99; 95% CI, 0.97-1.02; P = .58). However, cumulative PPI exposure was associated with increased mortality in patients without hospitalization for GIB (HR, 1.07 per 320 mg-months [omeprazole equivalents]; 95% CI, 1.06-1.08; P < .001). PPI exposure was significantly associated with severe infection (HR, 1.21; 95% CI, 1.18-1.24; P < .001) and decompensation (HR, 1.64; 95% CI, 1.61-1.68; P < .001). In a cause-specific mortality analysis, PPI exposure was associated with increased liver-related mortality (HR, 1.23; 95% CI, 1.19-1.28) but with decreased nonliver-related mortality (HR, 0.88; 95% CI, 0.85-0.91). CONCLUSIONS: PPI exposure is associated with increased risk of infection and decompensation in cirrhosis, which may mediate liver-related mortality. However, PPI use was associated with reduced all-cause mortality in those with prior GIB, suggesting benefit in the presence of an appropriate indication.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Mahmud N, Serper M, Taddei TH, et al. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology. 2022. PMID: 35398042. doi:10.1053/j.gastro.2022.03.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。